Canopy Biosciences
Canopy Biosciences is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants with Advanced Solid Tumors
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006)
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Randomized Study to Evaluate the Optimized dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) who have not previously received systemic treatment
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
AN OPEN-LABEL PHASE 2 STUDY TO EVALUATE PT2977 FOR THE TREATMENT OF VONHIPPEL-LINDAU DISEASE-ASSOCIATED RENAL CELL CARCINOMA
Sponsor Peloton Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
C4971006: A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION
Sponsor Pfizer Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by subcutaneous injection in nonambulatory participants with Duchenne Muscular Dystrophy
Sponsor Antisense Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
Sponsor Transposon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Sponsor Sellas Life Sciences Group Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Canopy Biosciences?
The 2026-10-09 snapshot links Canopy Biosciences to 8 distinct CTIS trials. Recorded services include Laboratory services, Exploratory biomarker testing on human blood samples, Primary/surrogate endpoint test, RNA testing, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Canopy Biosciences?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Canopy Biosciences conducted?
The linked trials record locations in 17 countries, including France, Spain, Italy, Germany, Denmark. These are trial locations, not confirmed office locations or countries where Canopy Biosciences delivered services.
What can this page tell me about Canopy Biosciences's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Canopy Biosciences. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Canopy Biosciences LLC